OS

IGEL Unveils New MSP Partner Program to Simplify the Delivery and Management of Secure Endpoints for Service Providers

Retrieved on: 
Wednesday, February 7, 2024
OS, Desktop, Data management, UMS, MSP, Security, Partner (business rank), Managed services, USD, VDI, Stiffness, Data as a service, Linux, Market, IGEL, Zero trust security model, Software as a service, Dentist, Pharmacy, Organization, Mobile phone

SAN FRANCISCO, Feb. 7, 2024 /PRNewswire/ -- IGEL, provider of the secure endpoint OS for now and next, today announced a new Managed Services Provider (MSP) partner program and MSP service models for the IGEL platform which enables secure access for VDI, DaaS, SaaS and secure browsing use cases. Designed to be easy, flexible and cost effective for MSPs looking to deliver secure managed endpoints with unprecedented simplicity, the new IGEL MSP partner program features both multi-tenant and single-tenant deployment options to serve varying customer requirements.

Key Points: 
  • Designed to be easy, flexible and cost effective for MSPs looking to deliver secure managed endpoints with unprecedented simplicity, the new IGEL MSP partner program features both multi-tenant and single-tenant deployment options to serve varying customer requirements.
  • "1 Meeting this need, IGEL is releasing MSP-optimized licensing for the IGEL platform, including the secure IGEL OS and IGEL Universal Management Suite (UMS), so that MSPs may enhance their digital workspace stack with a modern, secure and cost-effective endpoint service that scales with their business.
  • The new IGEL MSP partner program is a special designation offered to participating MSPs under the IGEL Velocity Partner Program.
  • "We strive to be both cutting-edge, and user friendly, and with the launch of the IGEL MSP Program we are able to optimize delivery of secure managed endpoints for all customers, regardless of size."

Beatbot AquaSense Series, the World's First 5-in-1 Robotic Pool Cleaner Captures 50% of High-End Market Demand in January

Retrieved on: 
Wednesday, February 7, 2024
OS, CES, IMU, Environment, MSRP, Sale, Trust, IP68, Cassette tape

RICHMOND, Texas, Feb. 7, 2024 /PRNewswire/ -- Beatbot, the tech innovator behind Aquasense Pro, a revolutionary pool robot featuring many groundbreaking industry-firsts, has received over 1000 pre-orders within just 30 days of unveiling the product at CES last month. 

Key Points: 
  • Since announcing the launch of the Aquasense Pro in January, Beatbot has successfully sold 1000 pre-sale units, solidifying its position as a market leader by capturing significant market demand of high-end robotic pool cleaners (priced over $1000), with 50% of online orders favoring Beatbot over its competitors.
  • To commemorate this success, Beatbot is extending a $300 discount for AquaSense and $400 discount for AquaSense Pro.
  • Beatbot AquaSense Pro addresses these concerns by introducing industry-first features:
    Intelligent Pool Cleaning with AI: Beatbot AquaSense Pro is the inaugural robotic pool cleaner employing true decision-making AI.
  • Fully Cordless and Highly Convenient: Beatbot AquaSense Pro eliminates the constraints of traditional pool cleaning devices by going cordless.

Korea University Researchers Unveil Benefits of Perioperative Radiotherapy for Treating Liver Cancer with High Recurrence Risk

Retrieved on: 
Wednesday, February 7, 2024
OS, Radiation therapy, Rated R, Hepatocellular carcinoma, Survival, Meta-analysis, Patient, HCC, Recurrence, Canadian International Council, Radiation, Disease, Risk, DFS, Neoplasm, Cancer, Liver cancer, Liver, Survival rate, Korea University, Pharmaceutical industry

SEOUL, South Korea, Feb. 7, 2024 /PRNewswire/ -- More than two-thirds of patients with hepatocellular carcinoma (HCC), who receive surgical interventions, experience recurrence owing to lack of an established perioperative treatment. Now, researchers from Korea University have performed a meta-analysis to examine the oncological benefits of administering radiotherapy before or after surgery. The findings suggest that perioperative radiotherapy decreases the chances of recurrence in patients, improving their survival rate.

Key Points: 
  • Researchers have found that radiotherapy during liver cancer surgery reduces chances of recurrence and boosts survival for high-risk patients.
  • Now, researchers from Korea University have performed a meta-analysis to examine the oncological benefits of administering radiotherapy before or after surgery.
  • The findings suggest that perioperative radiotherapy decreases the chances of recurrence in patients, improving their survival rate.
  • This emphasizes the need for an adjuvant treatment like radiotherapy along with surgery for treating HCC patients with a high risk of recurrence.

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Molecule, Royalty payment, Conference, Liver disease, Calendar, Breast, Immunotherapy, RCC, PIN, ASCO, NHT, Progression-free survival, Safety, FDA, PLK4, ADC, ITT, PKMYT1, Associate, University, Baylor University, PARP, USP1, Society, Neck, Science, Acquisition, Biology, Superior, Huntsman Cancer Institute, Dean (education), Metastasis, PFS, Translational research, Drug development, Distinguishing, Head, Food, NET, Baylor College of Medicine, Cancer, Share repurchase, BIRC, OS, SCCHN, Neoplasm, Congress, National Cancer Institute, Abbreviated New Drug Application, Research, Docetaxel, Translation, Prostate cancer, Therapy, ESMO, Education, Experiment, Checkmate, Pharmaceutical industry

In 2023, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.2 billion.

Key Points: 
  • In 2023, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.2 billion.
  • Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter and year ended December 31, 2023, Exelixis earned $40.7 million and $148.5 million, respectively, in royalty revenues.
  • In October 2023, detailed results were presented from the phase 3 CABINET pivotal trial at the 2023 ESMO Congress.
  • Exelixis management will discuss the company’s financial results for the fourth quarter and fiscal year of 2023 and provide a general business update during a conference call beginning at 5:00 p.m.

Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 6, 2024
Oncology, Health, Infectious Diseases, Hospitals, COVID-19, Pharmaceutical, Biotechnology, EPS, IPR, Compugen, Immunotherapy, Food and Drug Administration, ETR, Dow Jones Sustainability Indices, Progression-free survival, Obeldesivir, FDA, Virology, FTC, Hematology, ALL, HDV, Society, Neurotoxicity, Acquisition, HCV, Cell therapy, Acute lymphoblastic leukemia, MYR, Research, HIV, Patient, Tenofovir alafenamide, Food, Infection, Multiple myeloma, Standard of care, OS, Lymphoma, B-cell lymphoma, Table, GAAP, Docetaxel, Lung cancer, Science, Earnings per share, Investment, Liver disease, Risk, ASH, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023.
  • During the fourth quarter 2023, Gilead paid cash dividends of $943 million and utilized $150 million to repurchase common stock.
  • The Liver Disease portfolio sales were $691 million in the fourth quarter 2023 and remained flat compared to the same period in 2022.
  • Cell Therapy product sales increased 11% to $466 million in the fourth quarter 2023 compared to the same period in 2022.

AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist

Retrieved on: 
Tuesday, February 6, 2024
OS, Vanderbilt-Ingram Cancer Center, VEGFR, Survival, IO, TKI, Renal cell carcinoma, Division, RCC, MD, PFS, Safety, Patient, Progression-free survival, Sorafenib, Arm, Disease, ITT, Assistant, Oncology, LG Chem, Doctor of Philosophy, Pharmaceutical industry

The trial included a predefined subgroup of patients (26%) who were previously treated with both an immuno-oncology (IO) therapy and a VEGFR TKI.

Key Points: 
  • The trial included a predefined subgroup of patients (26%) who were previously treated with both an immuno-oncology (IO) therapy and a VEGFR TKI.
  • “For patients with relapsed or refractory advanced renal cell carcinoma, long-term progression-free survival is a vital measure of the value of anticancer therapy,” commented Michael Bailey, President and CEO of AVEO Oncology.
  • The trial randomized 350 patients to receive FOTIVDA (1.5 mg once daily) or sorafenib (400 mg twice daily).
  • The intent-to-treat (ITT) population included 175 patients in each arm; the safety population included 173 patients in the FOTIVDA arm and 170 in the sorafenib arm.

Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Pharmaceutical, Health, Oncology, OS, KIT, European, Investigational New Drug, Trial of the century, DNA, Research, Patient, IND, Autophagy, ASCO, GIST, Public expenditure, FDA, EMA, MAA, Part, Food, Society, TGCT, Gastrointestinal stromal tumor, European Medicines Agency, Sunitinib, Neoplasm, Cancer, INSIGHT, Tenosynovial giant cell tumor, NDA, Nature Medicine, Pharmaceutical industry

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.
  • Expects to present updated results from the Phase 1/2 study of vimseltinib in TGCT in the second half of 2024.
  • Expects to initiate a Phase 2 proof-of-concept study of vimseltinib for the treatment of chronic graft versus host disease (cGVHD) in the fourth quarter of 2024.
  • Cost of Sales: Cost of sales were $1.8 million in the fourth quarter of 2023, which includes $0.9 million in cost of product sales, compared to cost of product sales of $0.7 million for the fourth quarter of 2022.

IGEL and Midis Group Ink Strategic Go-to-Market Partnership to Open Dedicated IGEL Offices to Support Eastern Europe, Middle East and Africa

Retrieved on: 
Tuesday, February 6, 2024
Cloud, Partnership, IBM, OS, SAP, SAN, Dell, Emerging market, VDI, Dell Technologies, Citrix Systems, Data as a service, Linux, IGEL, Zero trust security model, Software as a service, Hewlett Packard Enterprise, HPE, Mobile phone

SAN FRANCISCO, Feb. 6, 2024 /PRNewswire/ -- IGEL, provider of the secure endpoint OS for now and next, and Midis Group, a technology partner with a network of 170 companies across 70 countries, today announced their strategic go-to-market partnership to expand IGEL's reach into Eastern Europe, the Middle East and Africa. The partnership gives IGEL dedicated on-the-ground resources across key emerging regions and opens new IGEL offices in UAE and Poland. Leveraging Midis Group's expansive network of value-added distribution and service providers and in-territory experts, the new partnership will accelerate the global adoption of IGEL OS, the secure endpoint OS designed for VDI, DaaS, SaaS and secure browsing.

Key Points: 
  • The partnership gives IGEL dedicated on-the-ground resources across key emerging regions and opens new IGEL offices in UAE and Poland.
  • Leveraging Midis Group's expansive network of value-added distribution and service providers and in-territory experts, the new partnership will accelerate the global adoption of IGEL OS, the secure endpoint OS designed for VDI, DaaS, SaaS and secure browsing.
  • With their dedicated resources behind us across Eastern Europe, the Middle East and Africa, we will unlock new opportunities for IGEL, growing our reach and market share faster."
  • "IGEL delivers a truly transformative solution for secure endpoint computing," said Ernest Sales, President Local Office and Co-President Retail at Midis Group.

IGEL and Midis Group Ink Strategic Go-to-Market Partnership to Open Dedicated IGEL Offices to Support Eastern Europe, Middle East and Africa

Retrieved on: 
Tuesday, February 6, 2024
Cloud, Partnership, IBM, OS, SAP, SAN, Dell, Emerging market, VDI, Dell Technologies, Citrix Systems, Data as a service, Linux, IGEL, Zero trust security model, Software as a service, Hewlett Packard Enterprise, HPE, Mobile phone

SAN FRANCISCO, Feb. 6, 2024 /PRNewswire/ -- IGEL, provider of the secure endpoint OS for now and next, and Midis Group, a technology partner with a network of 170 companies across 70 countries, today announced their strategic go-to-market partnership to expand IGEL's reach into Eastern Europe, the Middle East and Africa. The partnership gives IGEL dedicated on-the-ground resources across key emerging regions and opens new IGEL offices in UAE and Poland. Leveraging Midis Group's expansive network of value-added distribution and service providers and in-territory experts, the new partnership will accelerate the global adoption of IGEL OS, the secure endpoint OS designed for VDI, DaaS, SaaS and secure browsing.

Key Points: 
  • The partnership gives IGEL dedicated on-the-ground resources across key emerging regions and opens new IGEL offices in UAE and Poland.
  • Leveraging Midis Group's expansive network of value-added distribution and service providers and in-territory experts, the new partnership will accelerate the global adoption of IGEL OS, the secure endpoint OS designed for VDI, DaaS, SaaS and secure browsing.
  • With their dedicated resources behind us across Eastern Europe, the Middle East and Africa, we will unlock new opportunities for IGEL, growing our reach and market share faster."
  • "IGEL delivers a truly transformative solution for secure endpoint computing," said Ernest Sales, President Local Office and Co-President Retail at Midis Group.

Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts

Retrieved on: 
Monday, February 5, 2024
Injection, Serology, OS, Tumor microenvironment, Survival, Prostate cancer, Breast cancer, Immunotherapy, Pancreatic cancer, MD, PDAC, SITC, Enlightenment, Food and Drug Administration, Lung cancer, Society, Clinical trial, Therapy, Patient, Brain, Cancer, FDA, Biomarker, Trial of the century, Food, CADL, Fast track (FDA), CSO, Disease, Biology, Pancreatitis, Doctor of Philosophy, Valaciclovir, Conference, Pharmaceutical industry

“Candel is focused on delivering key value drivers to maximize the impact of its assets and to create substantial value to patients and other stakeholders.

Key Points: 
  • “Candel is focused on delivering key value drivers to maximize the impact of its assets and to create substantial value to patients and other stakeholders.
  • In 2023, we received Fast Track Designation from the FDA for CAN-2409, our most advanced product candidate, for both NSCLC and pancreatic cancer.
  • This platform is open for collaborations with external partners.”
    The Company's strategic prioritization of programs highlights Candel Therapeutics' commitment to operational excellence and efficiency.
  • This approach positions the Company for sustained success in the current dynamic market for new cancer therapeutics.